bluuebunny/crossref_metadata_2025_split huggingface dataset:
The correlation among tissue, serum adiponectin levels and histopathological variables in gastric cancer patients
Authors: Bilici A. , Guler D. O. , Seker M. , Ustaalioglu B. O. , Sonmez B. , Karaduman M. , Oncel M. , Gumus M. , Salepci T. , Yaylaci M. 
Published: August 2020

e22199 Background: Adiponectin is a new peptide hormone secreted from the adipose tissue, affecting the proliferation and insulin sensitivity in different cell types.The previous studies showed that the serum levels of adiponectin are decreased in patients with endometrial and breast cancer.In our study, demographic features and histopathological variables and the relationship among adiponectin levels of serum and gastric tissue were analyzed in gastric cancer patients. Methods: Thirty-five consecutive patients with gastric cancer included in this study.The serum levels of glucose, insulin, c-peptide, HbA1c, lipids and adiponectin were measured in patients.In addition, normal and tumor tissue levels of adiponectin were also detected.We analyzed the correlation among these parameters and patients demographic features, such as age, gender, body mass index (BMI) and histopathological variables. Results: Patients characteristics included 24 males (68.5%), 11 females (31.5%); median age was 64 (range:41–85). The mean serum, normal and tumor tissue levels of adiponectin were 49.4±0.8, 48.2±4.2, 48.6±2.9 ng/ml, respectively. There was no relationship among serum, normal and tumor tissue adiponectin levels (p>0.05).There was inverse correlation between the normal tissue levels of adiponectin and insulin (p=0.002).The serum adiponectin levels were significantly associated with tumor localization (p=0.03).However, there was inverse correlation between serum adiponectin levels and perineural invasion (p=0.02).In subgroup analysis, the serum, normal and tumor tissue levels of adiponectin in woman were not different compared with those in male patients (p>0.05).No relations were detected among tumor stage, grade, nodal status, lymphatic and vascular invasion, the other insulin-resistant status parameters and the levels of serum, normal and tumor tissue adiponectin (p>0.05). Conclusions: Our results suggest that no correlations among the levels of serum adiponectin,normal tissue and tumor tissue adiponectin levels,patients demographic features and histopathological variables except for the association of serum adiponectin with tumor localization and perineural invasion detected in gastric cancer patients. No significant financial relationships to disclose.
Clinical and pathological features of breast cancer in Arab compared to Jewish women in Northern Israel
Authors: Zidan J. , Geslikov M. 
Published: August 2020

e22201 Background: Breast cancer (BC) is the most common malignancy in both Jewish and Arab women in Israel. Although the incidence of BC is lower in Arab women it is diagnosed in younger age and seems to have worse prognosis. Recent data have suggested considerable molecular differences in BC from various ethnical groups. Molecular features are increasingly used for predicting cancer prognosis and response to treatment. The purpose of this study to compare clinical, pathological and molecular characteristics of BC in Arab and Jewish women in the Upper Galilee Methods: The files of 481 patients (pts) with breast cancer (BC) treated at the Oncology Institute, Ziv Medical Center between 2001 and 2007 were reviewed retrospectively. Type of breast operation and both clinical and all pathological findings of patients were summarized and correlated to the ethnicity of women. Results: Of the total 481 pts 380 were Jewish and 100 were Arab women. The main age at diagnosis was 49,4 years for Arabs and 59,5 years for Jews (p<0,01). At diagnosis 3% of Arab pts had DCIS compared to 7,4% in Jewish pts, stage I in 19% and 49,9%, stage II in 36% and 31,7%, stage III in 33,3% and 7,6%, stage IV in 9% and 3,7% of Arab and Jewish pts respectively (p<0,05). Well differentiated, moderately and poorly differentiated in 12%, 59% and 29% compared with 43,9%, 41,4% and 12,5% in Arabs versus Jews. Estrogen receptor was 69% in Arabs and 79% in Jews. HER-2 overexpression evaluated by IHC and CISH was diagnosed in 39% of Arab pts and in 24% Jewish pts (p<0,05). Lumpectomy was done in 36% in Arabs versus 64% in Jews (p<0,05). Conclusions: Our data demonstrate younger age and more advanced tumor at diagnosis in Arab compared to Jewish women. All pathological and molecular figures were more aggressive in Arab compared to Jewish women in Israel. Mammography for screening may be started at age 40 years in Arab women and treatment could be more aggressive. No significant financial relationships to disclose.
Expression of angiogenic genes in resectable non-small cell lung cancer (NSCLC)
Authors: Cabrera A. , Jantus Lewintre E. , Sirera R. , Honguero A. , Gil M. , Blasco A. , Sanmartin E. , Arnau A. , Guijarro R. , Camps C. 
Published: August 2020

e22207 Background: NSCLC is a major cause of cancer-related death worldwide. The prognosis for lung cancer patients is poor with 5-years survival rates being less than 15%. It is known that angiogenesis is an essential event for solid tumour growth. Vascular endothelial growth factor (VEGF) family of ligand and receptors (VEGFR) are described as powerful angiogenic factors. VEGF belongs to a protein family, within which Placental growth factor (PlGF) is a member, they bound to their receptors at the membrane levels, gathering a cascade of intracellular events. In this study, we examine the expression of angiogenic genes in NSCLC samples correlating the expression of these genes between them and with clinicopathological variables. Methods: We performed real-time quantitative polymerase chain reaction (RT-qPCR) to assess the expression of VEGF, PlGF, VEGFR1 and VEGFR2 in frozen lung cancer specimens from untreated NSCLC patients who had undergone surgical resection (n=21). For this purpose, RNA was extracted and RTqPCR was performed using TaqMan® probes. Relative quantification was calculated by Pfaffl formulae, using an endogenous gene for normalization. We correlate the expression of the angiogenic genes between them and with other biologic variables. Statistical analysis were done using the SPSS 13.0 software. Results: Our results show that tumor samples have higher expression of PlGF than normal tissue. The expression of PlGF and VEGF correlates with the expression of their receptors in the group of samples analyzed. The expression of VEGFR1 and VEGFR2 was also significant correlated. We found a significant correlation between the levels of expression of PlGF and the tumor size (p= 0.023, Spearman's test), whereas no relation was found between the expression of the genes and the histology or stage of disease. Conclusions: Our results reveal that, in NSCLC, PlGF mRNA is higher in tumor than in normal tissue and is positively correlated with the tumor size and with the expression of angiogenic receptors. Theses finding could indicate that PlGF have some role in lung cancer progression and may be a promising new biomarker in NSCLC, but still more investigations are necessary with a larger number of samples. Supported by Instituto de Salud Carlos III (Fondo de Investigación Sanitario Grant). No significant financial relationships to disclose.
Apoptotic genes as a prognostic factor in penile epidermoid carcinoma
Authors: Novais P. C. , Paula A. A. , Rodrigues A. A. , Barione D. F. , Peria F. M. , Tirapelli D. P. , Tucci S. , Cologna A. J. , Martins A. C. , Tirapelli L. F. 
Published: August 2020

e22208 Background: The penile cancer is a rare condition in European men. The treatment can cause physiological and/or psychological problems in patients. The comprehension of the disease behavior can provides new, non-invasive therapeutic interventions. For this reason, the protein expression of apoptotic genes (caspase-3, caspase-8, bcl-2) were analysed with the immunohistochemistry technique, correlating with tumor grade (I, II and III) and with the patient survival in order to understand the basic mechanism of tumoral transformation. It is beyond doubt that studies related with penile cancer and its mechanism of apoptosis is scarce in the literature. Therefore, this study can contribute with information about this disease. Methods: The immunohistochemistry reactions on 50 samples of squamous cell carcinoma were carried out with the avidina-biotina-imunoperoxidase method with antigen recovery. The analyses were made using the graduation method ‘in crosses‘ (0 to 4 crosses - no stain to more than 75% of positives cells) and in categories (low, intermediate, high) of the cytoplasm immunoreactivity of the epidermoide penile carcinoma cells. Results: It was observed a statistically significant difference when the expression of caspase-3 were compared with the grades I and II of the tumor (p=0.0010) and when comparing the patient survival with the grades I and II of the tumor (p=0.0212). The protein expression of caspase-3 and caspase-8 was lesser in relation to bcl-2, suggesting that the apoptotics rate in this carcinoma is low. The higher expression of the anti-apoptotic protein bcl-2 suggests a higher preservation of the tumoral cells. Conclusions: The analysis did not showed correlation between the proteins expression with the survival curve of patients. No significant financial relationships to disclose.
Circulating tumor DNA in plasma of breast cancer patients from India
Authors: Bhattacharyya S. , Raina V. , Shukla N. K. , Shukla S. , Kumar R. , Hedau S. , Kumar G. , Bharti A. C. , Rath G. K. , Das B. C. 
Published: August 2020

e22213 Background: Recently, breast cancer has become the most common cancer among women in all urban population in India. Annually about 80000 new cases and 40000 deaths occur and majority of breast cancers are pre-menopausal. Conventional diagnostic methods are not very sensitive especially in early stages of cancer. This necessitated a more sensitive and reliable method for early diagnosis leading to effective treatment, better prognosis and survival. Recently, the level of cell free circulating tumor DNA in blood plasma or serum of patients with variety of tumors are being considered as reliable non-invasive diagnostic tool but no study has been done in India. The present study has therefore been undertaken to evaluate clinical utility of cell free DNA as potential biomarkers for early diagnosis and management of breast cancer. Methods: 25 newly diagnosed untreated breast cancer patients and 25 healthy subjects having no sign of significant medical illness with informed consent were enrolled for the study. 9 patients after chemotherapy were also included in the study. Blood plasma collected from both patients and controls were employed for DNA isolation, using Qiagen kit. Concentration of cell free plasma DNA was analyzed by 3 methods viz. nanodrop spectro-photometry, integrated density value (IDV) of PCR products of Exon 7 of p53 gene and quantitative real time PCR (cycles threshold converted to genome equivalent). All values of DNA concentration obtained by three methods used as continuous variables and receiver operating characteristic (ROC) were plotted and the cut-of value was determined at 90% sensitivity and 100% specificity level of ROC. Results: Mean free plasma DNA concentration as determined by both Q-RT PCR and IDV in cancer patients was found to be significantly higher in advanced stage breast cancer patients than in controls (genome equivalent 18850 vs 431; IDV 17912 vs 4197; p=0.001). However, no significant difference could be observed in early stage disease as compared to controls possibly due small sample size. Conclusions: Free Plasma DNA concentration is a reliable molecular marker for detection of breast cancer and can serve as a prognostic indicator leading to its potential clinical application either alone or in combination with other conventional methods. No significant financial relationships to disclose.
Triple negative breast cancer: An institutional review
Authors: Dioca M. , Savignano M. , Gimenez L. , Marino L. , Delfino C. , Alvarez A. M. , Mickiewicz E. 
Published: August 2020

e22214 Background: Triple negative breast cancer (BC) is a distinct group of tumors that show common but heterogeneous morphologic, genetic, and immunophenotypic features. Despite differences in the definition and prevalence, it comprises 8% to 20% of all breast cancers and is associated with an aggressive clinical course with significant risk of either local or systemic relapse and subsequent increased risk of death on short term follow up (particularly in the first 5 years).We study the pathological characteristics and the clinical outcome of a cohort of 77 triple negative BC patients (pts) diagnosed at our Institution. Methods: Between January 1999 and September 2008, 77 (stage I to III) triple negative BC pts. were retrospectively analyzed. All pts had their receptor status, Her neu, ck-5, ck-6 and staining for EGFR by the same pathologist. Pathological parameters (Pp) analyzed were: status of axilary lymph nodes (LN), nuclear grade, histologic grade, mitotic index and vascular invasion and the use of antraciclins in the adjuvant setting. Univariate and multivariate analysis (proporcional hazard regression Cox model) for the Pp associated with relapse, and the log rank test to compare two curves of each Pp for disease free survival (DFS), and overall survival (OS) were performed. Results: The median age was 57.8 years (range 30–86 years).The median follow up time was 57.7 months (range, 4- 241). From 77 Pts. analized, 65 (84.4%) were basal-like and 43 (64.6%) of those were GH3. Stage at the time of presentation was: 16 (20,7%) stage I; 40 (51,9%) stage II; 21 (27,7%) stage III. Pre-menopausal status was 29,48% (23 pts.), and 61% (47 pts) were LN negative. Overall, relapse rate was 38.5 % (n= 30), 63 Pts (81.8%) are still alive. Median DFS was not reached. Global DFS and OS were 59% and 79% respectively, and status of LN was the only prognostic factor. LN- vs LN+ DFS (p< 00.02) and OS p (< 0.02).All others Pp analyzed were not statistically significative. Conclusions: Despite previous studies have demonstrated that triple negative is an independent marker of poor prognosis in BC as a whole, in the LN-negative, and LN-positive groups, in this basal like population only positive LN was an independent poor prognostic factor for DFS and OS. No significant financial relationships to disclose.
CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer
Authors: Efremidis A. P. , Fostira F. , Panopoulos C. , Papademitriou K. , Pistalmazian N. , Tsoukalas N. , Yannoukakos D. 
Published: August 2020

e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type. The autosomal dominantly inherited germline mutations of the E- cadherin (CDH1) gene are the defects underlying the HDGC syndrome. The median age of onset for diffuse gastric cancer is 38 years. CDH1 mutations are highly penetrant, conferring a cumulative risk of diffuse gastric cancer of 75%. Methods: Genomic DNA was purified from peripheral blood leukocytes following standard chloroform extraction. The complete coding sequences of the CDH1-gene, including splice junctions, were amplified by Polymerase Chain Reaction (PCR) and electrophorized in an ABI Prism 310 Genetic Analyzer. Results: A pathogenic mutation located on exon 7 of the CDH1 gene was identified in a female patient diagnosed with bilateral breast cancer at the age of 36. She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast. At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma. She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome. The nonsense mutation found was probably maternally inherited, since the maternal grandmother was diagnosed with breast cancer at the age of 38. Conclusions: The selection process of patients for genetic testing for the HDGC syndrome is not quite clear at the moment, as it is apparent that more types of breast cancer and not only lobular, can be associated with the syndrome. Criteria should be more flexible in respects to the histopathology of the cancer type. This is the first CDH1 mutation identified in a Greek patient. No significant financial relationships to disclose.
Biomarkers in cancer: Survey of diagnostic needs
Authors: Holzman T. , Gibbons W. 
Published: August 2020

e22222 Background: Much ongoing work in the field of diagnostics is related to identifying novel and clinically useful tumor markers. However, it is not clear that this discovery is focused on the clinical uses that are most important to physicians. Methods: Consequently, we conducted a survey to assess these needs. Our survey of oncologists, specialists and primary care physicians received 236 responses. Of these, 214 doctors provided their view, ranking with an 8 point Likert scale, for which of eight aspects of cancer that they would like to better differentially diagnose. Of the respondents, 45% were oncologists, 17% primary care, 16% urology and 15% OB/Gyn. Of the physicians surveyed, 57% were in private practice and 32% were in academic medicine, with the remaining 11% in a variety of other settings. Results: As may be unexpected, respondents believed that they still could benefit most from diagnosis itself (indexed score 6.1), followed closely by improving earlier diagnosis or identifying latent disease (5.6), as opposed to simple screening (4.82). The aspects that they believed required the least improvement were prognosis for metastasis (3.6) and prognosis for progression (4.0). Surprisingly, desire for the ability for better treatment planning was unremarkable as well (4.3). We also gauged the respondents familiarity with tumor markers using a 5 point Likert scale. 29% considered themselves very familiar, and only 13% considered themselves with less than average familiarity. Conclusions: The results of the survey suggest it may be useful to consider evaluation of biomarkers which aid early diagnosis rather than disease prognosis. [Table: see text]
Important serum markers in malignant lymphoma
Authors: Yavuz S. , Erkisi M. , Petekkaya I. , Basel N. 
Published: August 2020

e22225 Background: In this study, 78 patients with new diagnosed, 21 patients with relapsed malignant lymphoma who applied to Cukurova University Hospital between March 2006 - 2008, and 36 age and sex matched healthy control group were evaluated and have been followed up. Methods: The aim of this study was to investigate if; any acute phase reactants or lymphocyte markers in peripheral blood have any predictive role concerning the treatment response, or disease progression. Results: Peripheral blood CD20 (+) lymphocyte levels were slightly higher in new diagnosed patients (12.09±13.79), than the control group (11.25 ±4. 79) but, much lower in relapsed patients (7.30±9.51, P= 0.038). After the chemotherapy (CT), CD20 (+) cell percentage decreased significantly only in new diagnosed patients (p<0.001). Pretreatment CD20 (+) cell levels were higher in responding patients than no responders (15. 42 ± 13.30 versus, 6.72 ± 5.24 p= 0.052). Peripheral blood CD 4 (+) cell levels were below the healthy control group (p= 0.01) and remained low after the CT. Interestingly, CD8 (+) cell levels increased in responders, after the CT (p= 0.046) in both patient groups. CD 56(+) lymphocyte levels were higher only in new diagnosed patients than healthy group (p= 0.05). Its level increased further after the CT (p= 0.044). Serum TNF α levels were higher in patient groups than control (p<0.001). Its level decreased following CT (p= 0.002). CRP levels were higher in both patient groups and remained high following the CT (p<0.001), regardless of the response status. Ferritin levels were also higher in patients groups (p<0.001). Pre-treatment serum ferritin levels were lower in responders, than no responders (236.65 ± 242.17 ng/ml versus 718.77 ± 645.24 ng/ml, p= 0.02). Serum prealbumine levels were lower in lymphoma patients than the healthy controls (p< 0.001). Its level was increased after treatment, especially in patients with recurrent disease (21.15± 5.89 versus 26.60 ± 7.29 mg/dl, p= 0.019). Conclusions: In conclusion, it was decided that; during the different stages of lymphoma progression, several mutations may occur, in the different components of the host immune system. Some of the immune responses would continue in spite of complete clinical remission, as some others would predict the response. No significant financial relationships to disclose.
An RF hyperthermia electrode which generates no edge effect
Authors: Uchida N. , Moriyama M. , Kawaguchi A. , Yokokawa M. , Ikeda S. , Kitagaki H. , Kato H. 
Published: August 2020

e22229 Background: For local hyperthermia cancer therapy, radio frequency (RF) capacitive heating with a pair of electrodes is one of the most effective methods. RF hyperthermia with a conventional 2-dimensional square plate electrode produces an ‘edge effect‘ - the focusing of the RF current resulting in focal overheating. We designed and propose a novel hemispherical-shaped RF capacitive heating electrode that generates no edge effect. Methods: A CAD simulation (COMSOL Multiphysics 3.4) was done, and current and specific absorbance ratio (SAR) distributions of both the hemispherical and the conventional square plate shape electrodes were obtained by a 3-D finite element method. Results: The hemispherical electrode generated no focusing of current distribution, nor overheating with SAR elevation, while the square plate electrode produced an edge effect with local SAR elevation. Conclusions: The hemispherical electrode showed no edge effect from focal overheating. Our new electrode may be useful for local heating in the oral or vaginal cavity in clinical use. Phantom studies with a prototype electrode should be carried out for further confirmation. No significant financial relationships to disclose.
Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2
Authors: Gerard J. , Azria D. , Gourgou-Bourgade S. , Martel-Laffay I. , Hennequin C. , Etienne P. , Vendrely V. , Conroy T. , Francois E. , Montoto-Grillot C. 
Published: August 2020

LBA4007 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.
A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II)
Authors: James R. , Wan S. , Glynne-Jones R. , Sebag-Montefiore D. , Kadalayil L. , Northover J. , Cunningham D. , Meadows H. , Ledermann J. ,   National Cancer Research Institute (NCRI) ACT II Trial Management Group
Published: August 2020

LBA4009 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206
Authors: Rini B. I. , Halabi S. , Rosenberg J. , Stadler W. M. , Vaena D. A. , Atkins J. N. , Picus J. , Czaykowski P. , Dutcher J. , Small E. J. 
Published: August 2020

LBA5019 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]